Shaanxi Meibang Pharmaceutical Group Co., Ltd. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 905.41 million compared to CNY 841.93 million a year ago. Revenue was CNY 906.05 million compared to CNY 842.49 million a year ago.

Net income was CNY 145.09 million compared to CNY 125.74 million a year ago. Basic earnings per share from continuing operations was CNY 1.07 compared to CNY 1.14 a year ago. Diluted earnings per share from continuing operations was CNY 1.07 compared to CNY 1.14 a year ago.